Gurugram, India – 23rd September 2025: Agilus Diagnostics, a leading provider of diagnostic services in India and a subsidiary of Fortis Healthcare Ltd., proudly announces the launch of its ground-breaking AgilusEDGE Comprehensive Genomic Profile (CGP) Rapid at its state-of-the-art Reference Laboratory in Gurugram. This innovative test marks a transformative leap in cancer diagnostics by providing oncologists and clinicians with comprehensive genomic profiling of over 500 cancer-related genes in just four working days.

Traditionally, genomic profiling for cancer takes up to 30 days, often delaying critical treatment decisions. AgilusEDGE CGP Rapid, powered by advanced next-generation sequencing (NGS) technology, dramatically reduces this turnaround time, empowering oncologists with rapid, actionable insights to tailor personalised treatment plans. This establishes Agilus Diagnostics as the first commercial laboratory in India to deliver such lightning-fast, multi-gene profiling.

On the occasion, Dr Anand K, Managing Director & CEO at Agilus Diagnostics, said, “By bringing down the turnaround time for comprehensive genomic profiling from nearly a month to just four working days, Agilus Diagnostics has taken a decisive leap forward in cancer care. Being the first lab chain in India to introduce this capability, we are not only redefining industry benchmarks but also ensuring that patients and oncologists have faster access to critical insights when every day matters. This breakthrough reflects our commitment to making advanced, precision diagnostics led personalized medicine a reality for patients across India."

The AgilusEDGE CGP Rapid offers:

• Comprehensive profiling of 500+ genes relevant to targeted therapies and precision oncology.
• Turnaround time of 4 working days, compared to the industry standard of several weeks.
• Formalin-fixed paraffin-embedded (FFPE) tissue compatibility, ensuring easy integration into existing diagnostic workflows.

This launch reinforces Agilus Diagnostics’ leadership to advancing cancer care in India by bridging the gap between diagnosis and timely treatment, ultimately enhancing patient outcomes.

About Agilus Diagnostics

(A subsidiary of Fortis Healthcare Ltd.)

Instituted in 1995, Agilus Diagnostics Ltd., is one of India’s largest diagnostics service providers in terms of number of laboratories in India as of and for the financial year ended March 31, 2023 (Source: CRISIL Report). Agilus Diagnostics has a network of 410+ labs, 3700+ customer touch points, and 12000+ direct clients/pick up points spread across 1000+ cities, 25 states and five union territories in India as of March 31, 2023. The company has recently undergone a brand transformation journey and has adopted a new name Agilus Diagnostics. Agilus is a portmanteau of ‘Agile’ and ‘Us’ and is inspired from the Latin term ‘agilis’ which means ‘agility’. Agilus offers more than 3,000 tests and test combinations, ranging from routine tests to esoteric and genetic tests. The company has the largest number of NABL accredited labs in the country as of March 31, 2023 (Source: CRISIL Report) with 43 NABL accredited labs, 3 NABL M(EL)T certified labs and 2 CAP accredited labs. Its international network consists of centers across the SAARC region, Sub-Saharan Africa, South-East Asia and the Middle East. Agilus is committed to research and development and focused on genomics and ‘next-generation diagnostics’ and delivering a customer-centric experience through integrated and seamless technology platforms and data-driven actionable insights.